|
Gene: TMEM254 |
Gene summary for TMEM254 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TMEM254 | Gene ID | 80195 |
Gene name | transmembrane protein 254 | |
Gene Alias | C10orf57 | |
Cytomap | 10q22.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | B4DU43 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80195 | TMEM254 | C46 | Human | Oral cavity | OSCC | 2.77e-10 | 3.55e-01 | 0.1673 |
80195 | TMEM254 | C51 | Human | Oral cavity | OSCC | 3.69e-10 | 4.82e-01 | 0.2674 |
80195 | TMEM254 | C57 | Human | Oral cavity | OSCC | 4.29e-09 | 3.28e-01 | 0.1679 |
80195 | TMEM254 | C06 | Human | Oral cavity | OSCC | 1.43e-03 | 8.05e-01 | 0.2699 |
80195 | TMEM254 | C08 | Human | Oral cavity | OSCC | 2.11e-34 | 6.55e-01 | 0.1919 |
80195 | TMEM254 | LN22 | Human | Oral cavity | OSCC | 6.77e-03 | 4.39e-01 | 0.1733 |
80195 | TMEM254 | LN46 | Human | Oral cavity | OSCC | 7.70e-06 | 2.55e-01 | 0.1666 |
80195 | TMEM254 | LP15 | Human | Oral cavity | LP | 1.21e-02 | 6.31e-01 | 0.2174 |
80195 | TMEM254 | SYSMH1 | Human | Oral cavity | OSCC | 2.00e-03 | 1.83e-01 | 0.1127 |
80195 | TMEM254 | SYSMH2 | Human | Oral cavity | OSCC | 1.60e-05 | 2.18e-01 | 0.2326 |
80195 | TMEM254 | SYSMH3 | Human | Oral cavity | OSCC | 1.52e-09 | 2.05e-01 | 0.2442 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM254 | SNV | Missense_Mutation | novel | c.64A>C | p.Thr22Pro | p.T22P | Q8TBM7 | protein_coding | deleterious(0.02) | benign(0.202) | TCGA-D8-A1JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | ChemotherapyHormone Therapy | doxorubicine | SD |
TMEM254 | SNV | Missense_Mutation | rs144946848 | c.349N>T | p.Arg117Trp | p.R117W | Q8TBM7 | protein_coding | deleterious(0) | benign(0.409) | TCGA-C5-A1BJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM254 | SNV | Missense_Mutation | rs777639712 | c.355C>T | p.Arg119Cys | p.R119C | Q8TBM7 | protein_coding | deleterious(0.04) | possibly_damaging(0.629) | TCGA-AD-6963-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TMEM254 | SNV | Missense_Mutation | rs748149784 | c.274N>T | p.Arg92Trp | p.R92W | Q8TBM7 | protein_coding | tolerated(0.14) | benign(0.003) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMEM254 | SNV | Missense_Mutation | c.136N>A | p.Leu46Met | p.L46M | Q8TBM7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMEM254 | SNV | Missense_Mutation | rs749053952 | c.356G>A | p.Arg119His | p.R119H | Q8TBM7 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TMEM254 | SNV | Missense_Mutation | novel | c.134C>T | p.Pro45Leu | p.P45L | Q8TBM7 | protein_coding | tolerated(0.27) | benign(0.119) | TCGA-E6-A2P8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
TMEM254 | SNV | Missense_Mutation | c.291N>C | p.Trp97Cys | p.W97C | Q8TBM7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DD-A11C-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TMEM254 | SNV | Missense_Mutation | novel | c.40N>C | p.Ser14Arg | p.S14R | Q8TBM7 | protein_coding | tolerated(0.39) | benign(0.015) | TCGA-G3-A3CG-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Targeted Molecular therapy | sorafenib | SD |
TMEM254 | SNV | Missense_Mutation | c.106N>G | p.Gln36Glu | p.Q36E | Q8TBM7 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-91-6848-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |